Company
LON:ARIX
Arix Bioscience is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. The company collaborates with exceptional entrepreneurs and provide the capital, expertise and global networks needed to help accelerate their ideas into important new treatments for patients. As a listed company, it aims to bring this growth phase of the industry to a broader range of investors.
180 stories · page 8 of 9
Unlike most penem drugs, Iterum’s sulopenem can be taken orally, which is why analysts think it has the potential to become a blockbuster antibiotic drug
Ed Rayner is an investment director for major shareholder Arix Bioscience Plc (LSE:ARIX).
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
A look at some of the top risers and fallers in London on Thursday
The UK benchmark index of leading shares finished down nearly 32 points at 7,281
A look at some of the biggest risers and fallers on the London market this Tuesday
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Joe Anderson’s venture capital background made him an ideal fit for the CEO role during Arix’s early years, but the time has come for a new face to take the firm through its next stage of growth
Economists at ING said the August manufacturing data suggests “US business is weathering the protectionist storm for now"
Arix led a $24 million share placement and will invest $14.2 million in two tranches.
Chris Chipperton, a founder of the company, sold 3mln shares or around a third of his stake at 155p
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
A look at some of the top risers and fallers in London today
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Three of Arix's investee companies will be busy in the coming months, while a fourth now has the financial runway to expand its ground-breaking research
Investments and investor services
The quarterly update on the health of the UK economy showed something of a recovery from the snowed under first quarter.
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
A look at some of the top risers and fallers in London today
Arix led a A$24mln (£13.4mln) primary placing and will invest A$14.2mln itself in two tranches
